Paul Shabram PaxVax, Inc.

After a successful career as an entrepreneur in non-biological development and manufacturing, Mr. Shabram joined Chiron Corporation in the mid 1980’s. There he developed processes and cGMP systems including clinical production of therapuetc proteins. During the early 1990’s Mr. Shabram joined Canji (later to become Canji Schering-Plough) and applied the protein production and analytical methodology to create new technology for adenoviral vectors for gene therapy. With these methods, a new production technology suite was generated which vastly increased the productivity of viral culture and introduced chromatographic purification of viruses. The analytical and production methodology was used by a consortium of more than 20 companies in collaboration with the FDA to produce and make available the Adenovirus Reference Material through the American Tissue Culture Collection to eliminate some of the confusion created by different analytical methodologies. Mr. Shabram joined PaxVax in July 2007 as Vice President of Operations and was the first employee hired. His charge was to adapt modern adenoviral methods to an oral Ad 4 vector vaccine platform to enable clinical trials. An oral vector vaccine encoding an avian influenza hemagglutinin protein entered ongoing clinical trials in October 2009.  Several other programs have advanced the clinical stage.  Recently, the company began clinical trials for alive oral bacterial vaccine for the prevention of Cholera.